Skip to content
JNJJohnson & Johnson

What Is JNJ Fair Value?

Johnson & Johnson (JNJ) fair value estimate using multiple valuation models, updated daily.

As of September 15, 2026, Johnson & Johnson (JNJ) has a composite fair value estimate of $217.87 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $267.20, suggesting the stock is overvalued by 18.5%.

Data as of September 15, 2026 (today)

Composite Fair Value

Overvalued4 of 4 models

$217.87

vs. current price of $267.20(-18.5%)

Undervalued$217.87Overvalued
$267.20

How Is JNJ Fair Value Calculated?

Four independent models estimate what JNJ is worth. Each uses different inputs and assumptions. The composite blends them by weight.

JNJ Intrinsic Value

Forward-looking models based on future cash flows

DCF (Discounted Cash Flow)

35% weight

Estimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →

$320.82

+20.1%

Undervalued

Inputs used

FCF: 20.1BGrowth: 6.8%Discount: 6%

DDM (Dividend Discount Model)

15% weight

If a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →

$231.16

-13.5%

Fair Value

Inputs used

Dividend: $5.36/yrReq. Return: 6%Growth: 3.4%

JNJ Fair Value

Current fundamentals: earnings, assets, and growth rate

Graham Number (Value Investing)

25% weight

Created by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →

$93.73

-64.9%

Overvalued

Inputs used

EPS: $11.07Book Value: $35.28

PEG (Price/Earnings to Growth)

25% weight

Checks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.

$110.65

-58.6%

Overvalued

Inputs used

EPS: $11.07Growth: 6.8%

What If You Change the Assumptions?

Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.

Your DCF Fair Value

$320.82Undervalued

Current price $267.20 is 20.1% below this estimate

CheapFair ValueExpensive
6.8%
0.0%30.0%
5.7%
6.0%15.0%
2.5%
1.0%4.0%
15.0%
0.0%50.0%
View 10-year cash flow projections
YearProjected FCF (Free Cash Flow)Present Value
Year 1$21.47B$20.32B
Year 2$22.93B$20.53B
Year 3$24.48B$20.75B
Year 4$26.14B$20.98B
Year 5$27.92B$21.20B
Year 6$29.82B$21.43B
Year 7$31.84B$21.65B
Year 8$34.00B$21.89B
Year 9$36.31B$22.12B
Year 10$38.78B$22.35B
Terminal Value$1.26T$724.63B

What Are JNJ's Key Financial Metrics?

Earnings & Growth

Current Price

$267.20

EPS (TTM)

$8.63

Forward P/E

21.8

Profit Margin

21.5%

Cash & Balance Sheet

Free Cash Flow

16.9B

EBITDA

34.9B

Book Value

$35.28

Total Debt

49B

What Do Analysts Say About JNJ?

Low

$190.00

Average

$277.91

High

$320.00

Upside

+4.0%

Current $267.20Avg Target $277.91Buy22 analysts

JNJ Fair Value FAQ

What is the fair value of JNJ?

Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), JNJ's estimated fair value is $217.87. The stock is currently trading at $267.20, which makes it overvalued by our analysis.

How is JNJ's fair value calculated?

We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.

Is JNJ overvalued or undervalued?

Based on our analysis, JNJ is overvalued. The current price of $267.20 is 18.5% above our estimated fair value of $217.87.

What do Wall Street analysts say about JNJ?

22 analysts cover Johnson & Johnson with a consensus rating of "Buy." The average price target is $277.91, ranging from $190.00 to $320.00. This implies 4.0% upside from the current price.